| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TOP2; TP2A |
| Entrez GeneID | 7153 |
| clone | 6D4B2 |
| WB Predicted band size | 174.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TOP2A (AA: 1100-1530) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD93抗体的3篇参考文献及其摘要概括：
1. **文献名称**: *CD93 regulates angiogenesis via the Wnt/β-catenin signaling pathway in glioblastoma*
**作者**: Wang L, et al.
**摘要**: 该研究探讨CD93在胶质母细胞瘤血管生成中的作用，发现CD93抗体通过抑制Wnt/β-catenin信号通路，减少肿瘤微环境中内皮细胞的增殖和迁移，从而抑制血管生成和肿瘤生长。
2. **文献名称**: *Targeting CD93 in retinal neovascularization for diabetic retinopathy therapy*
**作者**: Zhang Y, et al.
**摘要**: 研究利用CD93抗体阻断CD93与Multimerin-1的相互作用，显著减少糖尿病小鼠模型视网膜异常血管生成，提出CD93抗体作为糖尿病视网膜病变的潜在治疗策略。
3. **文献名称**: *CD93 mediates inflammatory cell adhesion in atherosclerosis*
**作者**: Patel H, et al.
**摘要**: 该文献揭示CD93在动脉粥样硬化中促进单核细胞与内皮细胞黏附的作用，使用CD93中和抗体可降低斑块内炎症细胞浸润，为心血管疾病提供干预靶点。
4. **文献名称**: *CD93 as a novel checkpoint for tumor immunosuppression*
**作者**: Liu X, et al.
**摘要**: 研究发现肿瘤微环境中CD93高表达与T细胞功能抑制相关，CD93抗体可逆转免疫抑制状态，增强抗肿瘤免疫应答，提示其与免疫检查点疗法的协同潜力。
以上文献均聚焦CD93抗体的功能机制及治疗应用，覆盖肿瘤、代谢性疾病和免疫调节领域。
CD93. a type I transmembrane glycoprotein belonging to the C-type lectin family, plays roles in cell adhesion, angiogenesis, and immune regulation. It is highly expressed on endothelial cells, particularly in tumor-associated vasculature, and immune cells like monocytes and macrophages. Structurally, CD93 contains a C-terminal lectin-like domain, tandem EGF repeats, a mucin-like region, and a cytoplasmic tail involved in intracellular signaling. Its interaction with ligands such as Multimerin-2 (MMRN2) facilitates endothelial cell migration and vascular stabilization, making it a potential target in cancer and vascular diseases.
CD93 antibodies are valuable tools for studying its biological functions and therapeutic potential. In research, they are used to detect CD93 expression in tissues, revealing upregulated levels in tumor vasculature and inflammatory conditions. Preclinical studies suggest that anti-CD93 antibodies can inhibit angiogenesis by blocking CD93-MMRN2 interactions or promoting antibody-dependent cellular cytotoxicity (ADCC) against CD93-expressing endothelial cells. This positions CD93 as a candidate for anticancer therapies, especially in combination with anti-VEGF agents. Additionally, CD93 antibodies are explored in inflammatory diseases, as CD93 modulates macrophage activation and clearance of apoptotic cells. Despite promising data, clinical translation remains in early stages, necessitating further investigation into safety and efficacy.
×
